About Spruce Biosciences
Spruce Biosciences is a company based in San Francisco (United States) founded in 2014 by Alexis Howerton. Spruce Biosciences has raised $108 million across 3 funding rounds from investors including Citadel, Abingworth and 5AM Ventures. The company has 15 employees as of December 31, 2022. Spruce Biosciences offers products and services including TA-ERT. Spruce Biosciences operates in a competitive market with competitors including MBX Biosciences, Amolyt Pharma, OMass Therapeutics, Spruce and Sigilon, among others.
- Headquarter San Francisco, United States
- Employees 15 as on 31 Dec, 2022
- Founders Alexis Howerton
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Spruce Biosciences, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$108 M (USD)
in 3 rounds
-
Latest Funding Round
$53.62 M (USD), Post-IPO
Feb 09, 2023
-
Investors
Citadel
& 10 more
-
Employee Count
15
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Spruce Biosciences
Spruce Biosciences is a publicly listed company on the NASDAQ with ticker symbol SPRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Spruce Biosciences
Spruce Biosciences offers a comprehensive portfolio of products and services, including TA-ERT.
Targets Mucopolysaccharidosis Type IIIB to improve neurological outcomes.
People of Spruce Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Spruce Biosciences
Spruce Biosciences has successfully raised a total of $108M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $53.62 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Spruce Biosciences
Spruce Biosciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Abingworth and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked |
Investor details for Spruce Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spruce Biosciences
Investment portfolio details for Spruce Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Spruce Biosciences
Detailed financials for Spruce Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Spruce Biosciences Comparisons
Peer comparison for Spruce Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Spruce Biosciences
Spruce Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MBX Biosciences, Amolyt Pharma, OMass Therapeutics, Spruce and Sigilon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| Locked | Locked | Locked |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| Locked | Locked | Locked |
Spruce is engaged in providing real estate closing services.
|
|
| Locked | Locked | Locked |
Therapeutics for chronic diseases are developed via cell engineering platforms.
|
Detailed competitors of Spruce Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spruce Biosciences
Complete news archive for Spruce Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spruce Biosciences
Spruce Biosciences was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Spruce Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Richard King is the current CEO of Spruce Biosciences.
Spruce Biosciences is a funded company, having raised a total of $108M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Spruce Biosciences is 15.
Spruce Biosciences was founded in 2014 and is based in San Francisco, United States. As a clinical-stage biopharmaceutical company, small molecule therapeutics are developed for rare endocrine disorders impacting the hypothalamic-pituitary-adrenal axis. The lead program, SPR001, addresses congenital adrenal hyperplasia in both chronic and acute forms and is advancing through Phase 2 clinical trials. The mechanism of action for this oral candidate remains under investigation.
Spruce Biosciences's top competitors include MBX Biosciences, OMass Therapeutics and Spruce.
Spruce Biosciences offers TA-ERT.
Yes, Spruce Biosciences is publicly traded on NASDAQ under the ticker symbol SPRB.
Spruce Biosciences has 11 investors. Key investors include Citadel, Abingworth, 5AM Ventures, Healthcap, and Novo Holdings.
The ticker symbol of Spruce Biosciences is SPRB on NASDAQ.